Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + GM-CSF + radiotherapy in advanced solid tumors
ChiCTR2400082574Phase 2Not yet recruiting
- Sponsor
- Fuyang City Cancer Hospital
- Start
- Apr 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab and sargramostim in Non-hematologic malignancy, sponsored by Fuyang City Cancer Hospital. Primary endpoint: Objective response rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
envafolimabsargramostim
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2400082574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082574.